Fig. 4: Epithelial TGFβ/ALK5 signalling synergises with Wnt and MAPK signalling to accelerate tumourigenesis. | Nature Communications

Fig. 4: Epithelial TGFβ/ALK5 signalling synergises with Wnt and MAPK signalling to accelerate tumourigenesis.

From: Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features

Fig. 4: Epithelial TGFβ/ALK5 signalling synergises with Wnt and MAPK signalling to accelerate tumourigenesis.The alternative text for this image may have been generated using AI.

a Survival plot for VilCreER;Apcfl/+;KrasG12D/+;Alk5+/+ (n = 12, grey) and VilCreER;Apcfl/+;KrasG12D/+;Alk5CA (n = 22, red) mice aged until clinical endpoint following tamoxifen induction. P = 1.0 × 10−4, log-rank test. b, c Small intestinal (SI) tumour number (b) and burden (c) per mouse from mice described in a. n = 12 Alk5+/+ mice (grey), n = 16 Alk5CA mice (red) for tumour number dataset; n = 7 Alk5+/+ mice (grey), n = 15 Alk5CA mice (red) for tumour burden dataset. Data were ±s.e.m; P = 0.064 (b), P = 0.063 (c), two-tail Mann–Whitney U-test. d Relative percentage of small intestinal tumours from VilCreER;Apcfl/+;KrasG12D/+;Alk5CA (Alk5CA) mice positive (grey) or negative (blue) for Alk5CA expression (ISH). n = 4 mice. Data were ±s.e.m. e Representative IHC for p-ERK, β-catenin and p-SMAD3 on tumour tissue from mice described in a. Scale bar, 200 μm.

Back to article page